2G33
Human Hepatitis B Virus T=4 capsid, strain adyw
2G33 の概要
エントリーDOI | 10.2210/pdb2g33/pdb |
関連するPDBエントリー | 2g34 |
分子名称 | Core antigen (1 entity in total) |
機能のキーワード | virus, capsid, hepadnavirus, four-helix bundle, icosahedral |
由来する生物種 | Hepatitis B virus subtype adyw |
細胞内の位置 | Virion : P03147 |
タンパク質・核酸の鎖数 | 4 |
化学式量合計 | 67164.42 |
構造登録者 | |
主引用文献 | Bourne, C.R.,Finn, M.G.,Zlotnick, A. Global Structural Changes in Hepatitis B Virus Capsids Induced by the Assembly Effector HAP1. J.Virol., 80:11055-11061, 2006 Cited by PubMed Abstract: Hepatitis B virus (HBV) is a leading cause of liver disease and hepatocellular carcinoma; over 400 million people are chronically infected with HBV. Specific anti-HBV treatments, like most antivirals, target enzymes that are similar to host proteins. Virus capsid protein has no human homolog, making its assembly a promising but undeveloped therapeutic target. HAP1 [methyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate], a heteroaryldihydropyrimidine, is a potent HBV capsid assembly activator and misdirector. Knowledge of the structural basis for this activity would directly benefit the development of capsid-targeting therapeutic strategies. This report details the crystal structures of icosahedral HBV capsids with and without HAP1. We show that HAP1 leads to global structural changes by movements of subunits as connected rigid bodies. The observed movements cause the fivefold vertices to protrude from the liganded capsid, the threefold vertices to open, and the quasi-sixfold vertices to flatten, explaining the effects of HAP1 on assembled capsids and on the assembly process. We have identified a likely HAP1-binding site that bridges elements of secondary structure within a capsid-bound monomer, offering explanation for assembly activation. This site also interferes with interactions between capsid proteins, leading to quaternary changes and presumably assembly misdirection. These results demonstrate the plasticity of HBV capsids and the molecular basis for a tenable antiviral strategy. PubMed: 16943288DOI: 10.1128/JVI.00933-06 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (3.96 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード